MetaVia Inc. (MTVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.56M
Last updated: Nov 17, 2026 at 11:06 AM ET
MetaVia Inc. (MTVA) Competitors
The companies most similar to MetaVia are Biovie (BIVI), Quantum BioPharma (QNTM) and VistaGen Therapeutics (VTGN). By market cap, MetaVia ranks 9th of the 13 companies on this page; Tvardi Therapeutics (TVRD) is the largest at $15.74M.
Peer Comparison
MTVA's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| MetaVia (MTVA) | $8.56M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Quantum BioPharma Ltd. (QNTM) | $10.35M | N/A | N/A | 0.0% | -150.1% | 0.0% | 0.00% |
| VistaGen Therapeutics Inc (VTGN) | $8.01M | N/A | 3.4x | 0.0% | N/A | -46.5% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Phio Pharmaceuticals Corp (PHIO) | $9.21M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $10.12M | N/A | 14.5x | 0.0% | -150.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to MetaVia, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Quantum BioPharma Ltd. (QNTM) | Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. | QNTM competitors |
| VistaGen Therapeutics Inc (VTGN) | VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential... | VTGN competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Phio Pharmaceuticals Corp (PHIO) | Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts. | PHIO competitors |
Frequently Asked Questions About MTVA
Who are MetaVia's main competitors?
The companies most similar to MetaVia include Biovie (BIVI), Quantum BioPharma (QNTM), VistaGen Therapeutics (VTGN), Pluri (PLUR) and CytoMed Therapeutics Limited Ordinary Shares (GDTC), listed from the closest match.
Who is MetaVia's biggest competitor?
Tvardi Therapeutics (TVRD) is the largest of the similar companies at $15.74M; Biovie (BIVI) is the closest match by business profile, size, sector and industry.
How does MTVA stock compare with its competitors?
MTVA's net margin is 0.0% against a peer median of 0.0%.
Which of MetaVia's competitors pays a higher dividend?
MetaVia pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is MetaVia bigger than its competitors?
No. MetaVia is 9th by market cap among the 13 companies on this page; the largest is Tvardi Therapeutics (TVRD) at $15.74M.
MTVA pages: Overview, Earnings, Forecast, Financials, Competitors